Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Gemcitabine (Primary) ; Cisplatin
- Indications Mesothelioma
- Focus Adverse reactions
- 22 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 22 Mar 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 18 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.